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Introduction: The information available on the incidence and the characteristics of patients
with  acute renal failure (ARF) related to drugs is scarce.
Objectives: To estimate the incidence of drug-related ARF in hospitalised patients and to
compare their characteristics with those of patients with ARF due to other causes.
Material and methods: We  selected a prospective cohort of patients with ARF during hos-
pital  admission (July 2010–July 2011). Information on patients’ demographics, medical
antecedents, ARF risk factors, ARF severity according to the RIFLE classiﬁcation and hos-
pital drug administration was collected. We  analysed the relationship of drugs with the ARF
episodes using Spanish Pharmacovigilance System methods and algorithm.
Results: A total of 194 cases had an episode of hospital-acquired ARF. The median age of
patients was 72 years [IQR 20]; 60% were men. The ARF incidence during hospitalisation
was  9.6 per 1000 admissions. According to the RIFLE classiﬁcation, a risk of kidney damage
or  kidney injury was present in 77.8% of cases. In 105 (54.1%) cases, ARF was drug-related;
the drugs most frequently involved were diuretics, agents acting on the renin–angiotensin
system, immunosuppressants, -blocking agents, calcium channel blockers, contrast media
and non-steroid anti-inﬂammatory drugs. Patients with drug-related ARF had more  multi-
morbidity, fewer ARF risk factors and lower mortality.
Conclusions: Half of ARF episodes during hospitalisation were drug related. Patients with
drug-related ARF had higher cardiovascular morbidity than those with ARF related to other
causes, but they had a lower frequency of ARF risk factors and mortality. Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an©  2015 Sociedadopen access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Insuﬁciencia  renal  aguda  relacionada  con  medicamentos  en  pacientes
hospitalizados
Palabras clave:
Insuﬁciencia renal aguda
Medicamentos
Fármacos
r  e  s  u  m  e  n
Antecedentes: La información sobre la incidencia de insuﬁciencia renal aguda (IRA) intrahos-
pitalaria relacionada con medicamentos y las características de los pacientes es escasa.
Objetivo: Estimar la incidencia de IRA relacionada con medicamentos en pacientes hospi-
talizados y comparar sus características con las de los pacientes con IRA relacionada con
otras causas.
Métodos: Cohorte prospectiva de pacientes con IRA intrahospitalaria (julio de 2010-julio de
2011). Se recogió información sobre características y antecedentes de los pacientes, factores
de  riesgo y gravedad de la IRA según la clasiﬁcación RIFLE, y medicación durante la hospital-
ización. El análisis de la imputabilidad de los fármacos y la evaluación de la relación causal
se  realizó siguiendo los métodos y el algoritmo del Sistema Espan˜ol de Farmacovigilancia.
Resultados: Un total de 194 casos presentaron un episodio de IRA intrahospitalaria. La edad
mediana de los pacientes fue de 72 an˜os (RI 20); el 60% eran hombres. La incidencia de
IRA intrahospitalaria fue de 9,6 por cada 1.000 ingresos. Un 77,8% de los casos presentaron
riesgo o dan˜o renal según la clasiﬁcación RIFLE. En 105 (54,1%) casos, la IRA se relacionó
con  medicamentos; principalmente diuréticos, medicamentos que actúan sobre el sistema
renina-angiotensina, inmunosupresores, bloqueadores -adrenérgicos, bloqueantes de los
canales de calcio, medios de contraste y antiinﬂamatorios no esteroideos. La morbilidad
cardiovascular fue mayor y la frecuencia de factores de riesgo de IRA y la mortalidad menores
en  los pacientes con IRA relacionada con medicamentos.
Conclusiones: La mitad de los episodios de IRA intrahospitalaria se relacionaron con
medicamentos. Los pacientes con IRA relacionada con medicamentos presentaron más
antecedentes patológicos cardiovasculares, pero menos factores de riesgo de IRA y una
menor mortalidad.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Acute renal failure (ARF) is a common and severe complica-
tion that may develop during hospitalisation and may affect
between 5 and 7% of hospitalised patients, with a mortality
rate between 20 and 70%, irrespective of treatment.1 The inci-
dence of ARF depends on what deﬁnition of AKI was applied
in the speciﬁc study.2,3
Advanced age, males, infections, history of heart dis-
ease, and chronic renal failure (CRF) have been described
as some of the ARF-associated risk factors present during
hospitalisation.4,5 In addition to mortality, ARF increases
the risk of metabolic acidosis, hyperkalemia, arrhthmias,
gastrointestinal bleeding, and the risk of neurological abnor-
malities due to electrolytic imbalance.4 Based on the type
of study and the deﬁnition of ARF, 11–40% of patients
with ARF require dialysis during hospitalisation.4 More-
over, worse renal impairment is associated with prolonged
hospitalisation.6
Taking into consideration both community-acquired and
nosocomial episodes, drug-related ARF has been described
in 18–27% of overall IRA.7 Nevertheless, drugs have been
related to nosocomial ARF in up to 66% of patients older than
60 years.8 Drugs more  commonly associated with nosocomialARF are aminoglycosides, nonsteroidal anti-inﬂammatory
drugs (NSAIDs), piperacillin-tazobactam, amphotericin
B, combinations of trimethoprim with sulphonamides,
cyclosporine, and angiotensin-converting enzyme inhibitors
(ACEI).5
Several studies have described the frequency of ARF in
patients admitted in medical and surgical departments,5,8–16
as well as that of drug-related ARF,5,8–13 but none have com-
pared the characteristics and the morbi-mortality of patients
with drug-related ARF to patients vs ARF of other causes.
The main purpose of this study was to determine the inci-
dence of drug-related ARF in hospitalised patients, describe
the most common drugs causing ARF, associated risk fac-
tors, morbi-mortality, and compare these characteristics with
those observed in non-drug related ARF.
Methods
A prospective observational study was conducted in patients
who developed ARF during admission in a tertiary hospital in
Barcelona, between July 19th 2010 and July 31st 2011. Patients
were monitored until hospital discharge.
The inclusion criteria were adult patients with an increase
in serum creatinine of more  than 0.5 mg/dl observed in
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dence rate of ARF during hospitalisation was 1.4 per 1000n e f r o l o g i a. 2 0 
wo consecutive measurements during hospitalisation in
edical or surgical departments, if baseline concentration
as ≤2.5 mg/dl, or an increase in serum creatinine of more
hat 20%, in those patients with basal serum creatinine greater
han 2.5 mg/dl.1,2 Patients with an episode ARF at different
dmissions were enrolled.
Exclusion criteria were as follows: patients with no plasma
reatinine measurements available during hospitalisation and
efore screening of impaired renal function; patients admitted
ue to ARF, ﬂare of IRC, or renal transplants; patients under-
oing chronic dialysis; patients participating in clinical trials;
nd patients who  did not give their consent. Patients admit-
ed in traumatology, gynaecology and obstetrics departments
ere also excluded, as well as patients with ARF episodes in
ritical care units (e.g. patients in intensive care unit (ICU) or
atients with burns or bleeding) or in the post-surgery resus-
itation room.
Baseline plasma creatinine was deﬁned as mean creatinine
rom hospital admission and before meeting the inclusion
riteria. Patients with CRF before admission were enrolled
rovided that plasma creatinine remained stable at the time
f hospitalisation. Patients were screened via an electronic
rogramme that provided a daily list of those who met  the
nclusion criteria according to laboratory data. Each case was
alidated by a nephrologist.
Based on electronic clinical records, data on patients’
emographics (age and gender), admission department, hos-
ital stay, and medical history were collected. Information on
RF risk factors during admission (decompensated heart fail-
re or clinical evidence of heart failure, low blood pressure or
lood pressure below 90/60 mmHg, bleeding or any cause of
olume depletion as indicated in the clinical record) was also
ollected.
Data on the drugs administered during hospitalisation
active ingredients, dosing, and treatment duration) were col-
ected using the electronic medical prescription sheet. Drugs
ere classiﬁed using the Anatomical, Therapeutic, Chemical
ATC) Classiﬁcation System.17
Additionally, data on ARF complications during hospitali-
ation and discharge outcome (complete or partial recovery
f renal function, no recovery at all, and need of renal
eplacement treatment) were collected. The severity of ARF
as assessed based on the RIFLE classiﬁcation (risk, dam-
ge, failure, prolonged loss of renal function, and ﬁnal
nd irreversible failure of renal function).3 Data on dis-
harge diagnoses were coded according to the International
isease Classiﬁcation, Ninth Revision, Clinical Modiﬁcation
ICD-9-CM).18
The analysis of drug accountability and the assessment
f the causal relationship between drugs and ARF were con-
ucted according to the methods and the algorithm of the
panish System of Drug Surveillance (SEFV).19,20 These meth-
ds were used and agreed upon by 2 clinical pharmacologists
ere competent with its use. The assessment of the causal
elationship included the time elapsed between treatment
nitiation and the onset of ARF, previous knowledge of the
asual relationship between the drug and ARF, the effect of
he dechallenge and rechallenge of the suspected drug, and
ther alternative causes of ARF. Accountability was deter-
ined based on the outcome of the causality algorithm as well(6):523–532 525
as the existence of ARF risk factors. Categories of causality
were deﬁned as improbable, conditional, potential, probable
or deﬁnite.19,20 Only patients with drug-related ARF who had
at least one drug with deﬁnite, probable or potential were
included in the analysis. All ARFs in which the association of
the drugs prescribed during hospitalisation was conditional
or improbable were considered non-drug related. ARF aetiol-
ogy was thereby classiﬁed as pre-renal, renal, or post-renal
according to the Spanish Society of Nephrology guidelines
criteria.21
The incidence of nosocomial ARF (5–7%)1 and the number
of hospitalisations in a year were taken into consideration in
order to estimate the sample size. Two hundred and thirty-two
patients with ARF during hospitalisation had to be enrolled
in order to achieve a total of 20%7 drug-related ARFs during
admission, with a 95% conﬁdence interval (CI), and an accu-
racy of ±5%.
The study was conducted as per the national guidelines for
post-authorisation studies and was approved by the hospital
Clinical Research Ethics Committee.
The incidence (95% CI) of ARF among patients admitted in
the permissible hospital departments was estimated based on
ARF of any cause as a proportion of the total number of admis-
sions in these departments during the study period. Patients
complying with the inclusion criteria but did not give their
consent were also included to estimate total incidence. The
incidence (95% CI) of drug-related ARF was calculated by using
drug-related ARF cases as the numerator.
Categorical variables were expressed as frequencies
and proportions. Numeric variables were described as
means ± standard deviation (SD) or medians and interquartile
ranges (IR). Proportions were compared using the Chi-square
test. Means between the two groups were compared using the
Student t-test for independent groups or its non-parametric
alternative (Mann–Whitney U), based on each variable’s distri-
bution. A p value <0.05 was considered statistically signiﬁcant.
The statistical analysis was done through the statistical pro-
gramme  IBM SPSS Statistics version 20 (IBM Corp., New York,
US).
Results
One hundred and ninety-four cases of ARF during hospital-
isation, out of a total of 21,262 admissions, were included
during the study period (2 patients were admitted twice
and developed an episode of ARF at each admission).
A total of 20,807 admissions were excluded as they did
not comply with the study inclusion criteria for creati-
nine abnormalities and 261 were excluded for other reasons
(Fig. 1).
The incidence of ARF during hospitalisation and drug-
related ARF was 9.6 per 1000 admissions (95% CI: 8.4–11) and
4.9 per 1000 admissions (CI 95%: 4–6), respectively. The inci-beds-days (95% CI: 1.2–1.6).
For nosocomial ARF the median age was 72 years (IR 20)
and 60% of patients were male. The main demographics and
the medical history of patients are described in Table 1.
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Abbreviation: ARF, acute renal failure
Total inpatients
n=21 262
Did not meet creatinine criteria: (20 807)
On two consecutive analyses:
Eligible
455
 Excluded (261)
•  ARF in critical care unit (85) 
•  Admitted with ARF (82) 
•  On long-term dialysis (57) 
•  Admitted for acute renal transplant (15) 
•  Not confirmed by a nephrologist (10) 
•  Enrolled in clinical trial (1) 
•  Did not give consent (11)   
Included
194
105 with drug-related ARF 89 with ARF due to other causes 
•  ↑   ≥0.5 mg/dL if baseline creatinine  ≤2.5 mg/dL, or
•  ↑ 20% if baseline creatinine >2.5 mg/dL
Fig. 1 – Flow chart of admissions due to ARF during hospitalisation.A total of 47.9% of patients were admitted in the surgi-
cal department, whereas 52.1% of patients were admitted in
the medical department. The most common diagnoses lead-
ing to admission included: neoplasia (n = 58; 29.8%), infectious
disease (n = 18; 9.2%), and non-renal transplant (n = 16; 8.2%).
Mean hospital stay was 25.6 ± 20.4 days and mean time from
admission to compliance with the study inclusion criteria for
ARF was 11.9 ± 11.9 days.
A 50–99% increase in creatinine from baseline was reported
in half of the cases. A risk of renal damage was observed
in 29.9% of patients and 47.9% developed renal damage
according to the RIFLE classiﬁcation (Table 2). Hyperpotas-
saemia was the most common ARF-related complication
during hospitalisation (25.8%), followed by decompensated
heart failure (12.9%), arrhythmia (4.1%), and digestive bleeding
(3.6%).
Complete, partial or incomplete recovery of renal function
at discharge was reported in 95 (62.1%), 39 (25.5%), and 19
(12.4%) patients, respectively. Eight (4.1%) patients required
haemodialysis, which was continued in 2 patients after dis-
charge. Mortality during hospitalisation in patients with ARFwas of 22.4%. For patients with a fatal outcome, death was
related to ARF in 11 (5.7%) patients.
Impaired renal function was unrelated to drugs in 89
(45.9%) patients. Aetiology was pre-renal in 74 (83.1%) patients,
renal in 10 (11.3%), and post-renal in 5 (5.6%) (Fig. 2).
Impaired renal function was related to drugs in 105 (54.1%)
patients (Fig. 1). Drug accountability was classiﬁed as possible,
probable, and deﬁnite in 22 (21%), 70 (66.6%), and 13 (12.4%)
patients, respectively. However, there were one or more  risk
factors in 84.7% of drug-related cases (Table 1).
There were 305 drugs involved in the 105 drug-related
ARF cases. Subgroups of the most common drugs were
diuretics (33.4%, mainly furosemide), agents acting on
the renin–angiotensin system (17.3%, mainly enalapril),
-adrenergic blockers (7.2%, mainly bisoprolol), immunosup-
pressors (7.5%, mainly tacrolimus), iodinated contrast (5.9%),
and NSAIDs (5.5%) (Table 3). ARF was related to a single sus-
pected drug in 20.0% of cases (diuretics and radio imaging
contrasts were the most common, followed by ACEIs and
NSAIDs), with 2 drugs in 22%, 3 drugs in 24%, 4 in 18%, and
5 or more  in 16% of cases. The most common concomitant
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Table 1 – Baseline characteristics.
Characteristics Drug-related ARF
n = 105
Non-drug related
ARF
n = 89
p  Nosocomial ARF
n = 194
Age, years, median [IR] 72 [18] 73 [22.5] 0.86 72 [20]
>64 years, n (%) 72 (68.6) 57 (64.0) 0.54 129 (66.5)
Gender, men, n (%) 66 (63.0) 51 (57.3) 0.46 117 (60.0)
Medical history, n (%)
High blood pressure 78 (74.3) 52 (58.4) 0.02 130 (67.0)
Heart failure 28 (26.7) 13 (14.6) 0.05 41 (21.1)
Ischaemic cardiopathy 24 (23.0) 12 (13.5) 0.10 36 (18.6)
Diabetes mellitus 42  (40.0) 27 (30.3) 0.17 69 (35.6)
Chronic renal failure 37 (35.2) 36 (40.4) 0.46 73 (37.6)
Two or more 63 (60.0) 40 (45.0) 0.04 103 (53.1)
Admitting service, n (%)
Surgical 53 (50.5) 40 (44.9) 0.47 93 (47.9)
Medical 52 (49.5) 49 (55.1) 101 (52.1)
Days from admission to ARF, mean (DE) 11.8 (±9.1) 12 (±14) 0.56 11.9 (±11.9)
Creatinine prior to ARF, (mg/dl), mean (DE) 1.24 (±0.46) 1.29 (±0.69) 0.95 1.26 (±0.58)
Maximum creatinine during ARF, (mg/dl), mean (DE) 2.72 (±1.04) 3.76 (±2.11) <0.001 3.2 (±1.71)
Risk factors, n (%)
Volume depletion 40 (38.1) 42 (47.2) 0.24 82 (42.3)
Low blood pressure 26 (24.8) 35 (39.3) 0.03 61 (31.4)
Decompensated heart failure 20 (19.0) 17 (19.1) 1.00 37 (19.1)
Bleeding (from surgery site or a different site) 8 (7.6) 14 (15.7) 0.11 22 (11.3)
No. of Risk factors, n (%)
One 50 (47.6) 43 (48.3) 93 (47.9)
Two 29 (27.6) 20 (22.5) <0.001 49 (25.3)
Three or more 10 (9.5) 26 (29.2) 36 (18.5)
ARF: acute renal failure; IR: inter-quartile range; SD: standard deviation.
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uspected drugs were diuretics and an agent acting on the
enin–angiotensin system, alone or in combination with a
hird drug or more  suspected drugs (36 cases, 34.3%).
Patients with drug-related ARF more  commonly had a his-
ory of two or more  previous pathological events, as well as
istory of high blood pressure and heart failure compared to
atients with non-drug related ARF (Table 1). However, they
ess often had three or more  risk factors of ARF and low blood
Table 2 – Severity of ARF.
Severity Drug-related ARF
n = 105
Non-drug
AR
n = 
Increased creatinine, n (%)
≥50% 58 (55.2) 38 (42
≥100% 28 (26.7) 32 (36
≥200% 19 (18.1) 19 (21
RIFLE classiﬁcation, n (%)
Risk 39 (37.1) 19 (21
Injury 46 (43.8) 47 (52
Failure 20 (19.0) 23 (25
ARF: acute renal failure.
P value was determined using a Chi-square test.–Whitney U-test.
pressure and in turn, they often had three or more  risk factors
of ARF and low blood pressure, and mean maximum creatinine
was lower (Table 1). Furthermore, mortality during hospitali-
sation was lower among patients with drug-related ARF than
in patients with ARF related to other causes (7.7% compared
to 39.3%; p < 0.001). The most common cause of death in both
groups was neoplasia. Four patients with drug-related ARF and
7 patients with ARF related to other causes died of ARF.
 related
F
89
p  Nosocomial ARF
n = 194
.7) 0.21 96 (49.5)
.0) 60 (30.9)
.3) 38 (19.6)
.3) 0.05 58 (29.9)
.8) 93 (47.9)
.8) 43 (22.2)
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In cases of ARF not related to medication  the probability of causality was improbable in 79 cases (89%) and  
conditional in 10 cases (11%).
ARF not related to medication
N (%)
89 (100%)  
Pre-renal
74 (83.2%)
Intrinsic renal
10 (11.2)
Post-renal
5 (5.6)
• Neoplasia, 5 (5.6) 
Ischaemia, 3 (3.4): Extra-renal obstruction
of  collecting system,
5 (5.6):• Renal infarct, 3 (3.4)
Endogenous nephrotoxins, 7 (7.8):
• Tubular proteins:
o Myeloma, 1 (1.1)
• Intratubular pigments:
o Hyperbilirubinaemia, 5 (5.6)
o Hypercalcaemia, 1 (1.1)
Absolute reduction in plasma volume, 18 (20.2):
• Bleeding, 12 (13.4):
o Bleeding from a surgical site, 6 (6.7)
o Gastrointestinal bleeding, 4 (4.4)
o Macroscopic haematuria, 2 (2.3)
• Volume depletion, 6 (6.8):
o Diarrhoea, 3 (3.4)
o Dehydration, 3 (3.4)
Relative reduction in plasma volume, 56 (62.9):
• Decompensated heart failure, 17 (19.2)
• Third space losses, 11 (12.3)
• Sepsis, 11 (12.3)
• Decompensated cirrhosis of the liver, 5 (5.6)
• Hepatorenal syndrome, 5 (5.6)
• Rejection of transplanted organ, 5 (5.6)
• Acute pancreatitis, 2 (2.3)
Fig. 2 – Classiﬁcation and main causes of non-drug related ARF.Discussion
In our study, 10 in every 1000 admissions developed an episode
of ARF during hospitalisation and the episode was related
to drugs in half of the cases. Drugs were the only risk fac-
tor in only 15% of drug-related cases; the remaining patients
also had one or more  risk factors. The most commonly
used drugs were diuretics and ACEI or angiotensin recep-
tor antagonists (ARA II), followed by -adrenergic blockers
and calcium channel blockers, immunosuppressors, contrast
means, and NSAIDs. Patients who developed drug-relatedARF during admission more  commonly had a history of
two or more  previous pathological events; in turn, they
had less risk factors of ARF, lower creatinine levels during
the episode, and lower mortality. The frequency of noso-
comial ARF5,8–15 and their aetiology, including drug-related
ARF, have been described in several studies.5,8–13 However,
this study uses an algorithm to determine the causal rela-
tionship between drugs and ARF and provides a detailed
description of the characteristics of patients with drug-related
ARF.
The incidence of nosocomial ARF described in studies has
been variable, ranging from 0.16% in the Lian˜o et al. study,15
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Table 3 – Treatment groups, subgroups, and drugs related to ARF.
Treatment groups
n = 305 (%)
Subgroups
n  = 305 (%)
Drugs
n  = 305 (%)
Cardiovascular system 221 (72.4) Diuretics 102 (33.4) Furosemide 70 (22.9)
Hydrochlorothiazide 19 (6.2)
Spironolactone 13 (4.3)
Active agents in the
renin–angiotensin system 53 (17.4)
Enalapril 23 (7.5)
Losartan 17 (5.6)
Captopril 13 (4.3)
Beta-blockers 22 (7.2) Bisoprolol 6 (1.9)
Labetalol 4 (1.3)
Atenolol 4 (1.3)
Carvedilol 3 (1.0)
Nadolol 3 (1.0)
Propranolol 2 (0.7)
Calcium-channel blockers 21 (6.9) Amlodipine 14 (4.6)
Nifedipine 5 (1.7)
Diltiazem 1 (0.3)
Nimodipine 1 (0.3)
Cardiac therapy 15 (4.9) Nitroglycerine 11 (3.6)
Isosorbide mononitrate 2 (0.7)
Ivabradine 1 (0.3)
Amiodarone 1 (0.3)
Cardiovascular system 221 (72.4) Anti-hypertensives 8 (2.6) Doxazosin 7 (2.3)
Hydralazine 1 (0.3)
Antineoplastic and
immunomodulating agents 30 (9.8)
Immunosuppressors 23 (7.5) Tacrolimus 16 (5.1)
Mycophenolate mofetil 3 (1.0)
Cyclosporine 2 (0.7)
Everolimus 2 (0.7)
Anti-neoplastic agents 7 (2.3) Citarabine 2 (0.7)
Carmustine 1 (0.3)
Rituximab 1 (0.3)
Melfalan 1 (0.3)
Bortezomib 1 (0.3)
Etoposide 1 (0.3)
Several 18 (5.9) Radiocontrast agents 18 (5.9) Ioversol 7 (2.3)
Iobitridol 3 (1.0)
Iomeprol 2 (0.7)
Iohexol 1 (0.3)
Iopamidol 3 (1.0)
Iopromide 2 (0.7)
Musculoskeletal system 17 (5.5) NSAIDs 17 (5.5) Dexketoprofen 16 (5.2)
Ibuprofen 1 (0.3)
Systemic anti-infective agents 10 (3.3) Antibacterials 4 (1.3) Vancomycin 2 (0.7)
Trimethoprim-Sulfamethoxazole 2 (0.7)
Antifungals 3 (1.0)
Antivirals 3 (1.0)
amphotericin b 3 (1.0)
Acyclovir 1 (0.3)
Ganciclovir 1 (0.3)
Valganciclovir 1 (0.3)
Blood and haematopoietic organs 5 (1.6) Platelet aggregation inhibitors 5 (1.6) Acetylsalicylic Acid 5 (1.6)
Urogenital tract and sex hormones 3 (1.0) Alpha-adrenergic antagonists 3 (1.0) Tamsulosin 3 (1.0)
Nervous system 1 (0.3) Antiepileptics 1 (0.3) Pregabalin 1 (0.3)
ARF: acute renal failure; NSAID: nonsteroidal anti-inﬂammatory drugs.
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so 22.7% reported by Wang et al.16 The incidence observed
n our study was similar to that described by Kohli et al.8
1.4%), Lauzurica et al.11 (1.6%), and Shusterman et al. (1.9%)10
hese differences in the incidence of ARF reported in studies
ay result from the various ARF deﬁnitions used, and fromhe modiﬁed inclusion criteria. In the Barrantes et al. trial,13
he incidence of ARF was higher (12.6%) compared to our
tudy despite inclusion and exclusion criteria being similar.Nevertheless, a wider deﬁnition of ARF (increased creatinine
of 0.3 mg/dl or higher in any 48 h-period) was used and inci-
dence was estimated based on eligible patients rather than on
the total number of admissions.
In the present study, nosocomial ARF patients were older,
and there were more  male cases. Over 50% had a mean of
2 or more  previous pathological events, and almost 40% had
CRF. These characteristics are similar to those described in
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the cohort of patients with nosocomial ARF in the study of
Barrantes et al.,13 although the proportion of patients with
CRF in this study was even higher (52.1%) and women were
more  affected (53.6%). In the Kohli et al.8 and Lian˜o et al.15
studies from previous years, the mean age was lower, as
was the frequency of CRF reported by Kohli et al.8 How-
ever, patients currently admitted in hospitals are older, they
have more  comorbidities, and more  diagnostic and thera-
peutic procedures, with a potentially high risk of kidney
injuries.22
Almost 80% of patients in our study were at risk of renal
damage or developed renal damage during the episode of
ARF as per the RIFLE classiﬁcation (Table 2). The severity
of ARF cannot be compared with that of other studies as
they did not use the RIFLE classiﬁcation; however, the pro-
portion of patients requiring dialysis in our study (4.1%) was
lower than that described in other studies.5,8 This can be
explained by the fact that no ARF episodes reported in cases
admitted to critical care departments were included in our
study.
Furthermore, mean hospital stay from patients in the study
trebled that of patients admitted in general to hospital (8.7
days) during the study period. In several studies, mean hos-
pital stay of patients with nosocomial ARF has been higher
than that of patients without this complication.10,13 Noso-
comial ARF was also associated with higher mortality,10,13
even in patients not requiring critical care.13 Mortality rates in
patients with nosocomial ARF ranges from 10.8% in the Wang
et al.16 study to 32% in the Hou et al. study.9 In our study the
mortality was higher than the mortality described in the study
by Barrantes et al. (14.8%), although the cause of most deaths
was not ARF.
Use of drugs is known to result in ARF. Several authors
have studied the most common drugs, the mechanisms, and
predisposing factors involved in acquiring ARF.23–26 The fre-
quency of drug-related ARF described in Kohli et al.8 and
Barrantes et al. studies13 (66 and 72.3%, respectively) is sim-
ilar to that from our study. In contrast, Nash et al.5 and Jha
et al.12 describe a lower frequency (16 and 29%, respectively).
Only nosocomial ARF episodes were considered in all of these
studies, and ARF episodes from patients admitted in the ICU
were excluded in the Barrantes et al. study only,13 similar to
our study.
Diuretics, followed by ACEI and ARA II, have been more
commonly associated with ARF episodes. Concomitant use
of diuretics and renin–angiotensin antagonists, alone or with
other drugs, have been reported in almost 40% of drug-related
ARF episodes in our study. Each of these drugs may affect renal
function due to several mechanisms and, when used in com-
bination, can lead to increased risk of acute renal injury.27,28
NSAIDs are renown nephrotoxic agents.29 Increased risk of
acute renal injury has been described in a recent study when
NSAIDs are added to the treatment with at least 2 of the
following antihypertensive drugs: diuretics, ACEI or ARA II.30
NSAIDs5,8,13 as well as ACEI5,8,13 and diuretics11 have also been
related to nosocomial ARF in other studies. Unlike a num-
5,8–11ber of previous studies, aminoglucosides have not been
the main cause of drug-related ARF in this study, probably as
a result of the lower use at present.31,32 In addtion, no ARF
cases related to -lactamic antibiotics or quinolones, often;3 5(6):523–532
associated with interstitial nephritis, were reported23,33 in
this study. In fact no cases of acute interstitial nephri-
tis were identiﬁed in our study. Other drugs, including the
anti-hypertensives such as amlodipine or bisoprolol, immuno-
suppressors such as tacrolimus, and contrast media, have also
been related to ARF episodes. Tacrolimus, an immunosuppres-
sor commonly used to prevent solid organ transplant rejection
and to treat immune systemic diseases, is a known nephro-
toxic drug.34,35 On the other hand, contrast media still result in
impaired renal function in hospitals, in spite of recommended
preventive measures.36–38
Medical history including high blood pressure or heart
failure was more  common among patients developing drug-
related ARF during hospitalisation, and use of cardiovascular
drugs were most commonly involved in ARF episodes during
hospitalisation. Also, these patients are especially prone to
impaired renal function during admission. In order to prevent
ARF episodes in these patients special attention should be
paid to dosing of cardiovascular drugs, especially diuretics and
other anti-hypertensives. Also certain combinations, includ-
ing NSAIDs, should be restricted. Moreover, some risk factors,
including volume depletion, dehydration, and low blood pres-
sure during hospitalisation, should be avoided where possible.
Most patients developing a drug-induced ARF episode in our
study had 1 or 2 concomitant risk factors. In the Kohli et al.
study most drug-related cases were also accompanied by other
risk factors.8
This study has a number of limitations. Even though it is a
single-centre study, we  think the results may be extrapolated
to other hospitals of similar characteristics. The study took
place in a tertiary hospital with all medical and surgical spe-
cialties available, and the level of complexity is similar to that
of other hospitals sharing the same features.
The clinical records of the cases were used to obtain the
ARF risk factors. In light of this, some data may have been
omitted, although this data was not clinically relevant.
The strengths of our study lie in the fact that it has
a prospective design and that impaired renal function was
screened via an electronic programme. This allowed for
a reliable estimate of the incidence of nosocomial ARF.
Also, a standardised and reproducible method was used to
determine the causal relationship between drugs and ARF
episodes.
In conclusion, half of the ARF episodes developed dur-
ing hospitalisation in medical and surgical departments were
drug-related in our study. The most common drugs used for
the treatment of cardiovascular diseases, included diuretics
or renin–angiotensin inhibitors, or others like immunosup-
pressors, contrast media, and NSAIDs. In addition, patients
with drug-related ARF episodes were more  prone to have
cardiovascular events. In order to avoid ARF episodes dur-
ing hospitalisation among these patients, these drugs should
be carefully dosed and certain drug combinations should be
avoided, while paying special attention to the presence of
potential risk factors.Conﬂicts  of  interest
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